X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 27.1% in December

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 3,155,605 shares, a growth of 27.1% from the November 30th total of 2,482,029 shares. Approximately 3.7% of the shares of the stock are sold short. Based on an average daily volume of 747,734 shares, the days-to-cover ratio is presently 4.2 days. Based on an average daily volume of 747,734 shares, the days-to-cover ratio is presently 4.2 days. Approximately 3.7% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several research analysts have recently weighed in on XFOR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Monday. Stifel Nicolaus set a $10.00 price objective on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 5th. Zacks Research lowered shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Finally, Wall Street Zen downgraded shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $34.50.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, Chairman Adam R. Craig acquired 86,206 shares of the company’s stock in a transaction on Thursday, October 23rd. The shares were bought at an average cost of $2.90 per share, with a total value of $249,997.40. Following the completion of the acquisition, the chairman owned 376,087 shares in the company, valued at approximately $1,090,652.30. This trade represents a 29.74% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.15% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers grew its position in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares in the last quarter. Two Sigma Investments LP acquired a new position in X4 Pharmaceuticals during the third quarter worth $47,000. Bank of America Corp DE boosted its stake in X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after buying an additional 22,485 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in X4 Pharmaceuticals by 9.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock valued at $114,000 after buying an additional 43,320 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in shares of X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after acquiring an additional 51,544 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Trading Down 3.3%

Shares of XFOR stock opened at $4.16 on Wednesday. X4 Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $26.83. The company has a debt-to-equity ratio of 1.23, a quick ratio of 5.48 and a current ratio of 5.65. The stock’s fifty day moving average is $3.77 and its two-hundred day moving average is $3.05. The firm has a market capitalization of $363.74 million, a P/E ratio of -0.41 and a beta of 0.42.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.10. The business had revenue of $1.77 million during the quarter, compared to analyst estimates of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. Research analysts expect that X4 Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.